USD 136.25
(-0.67%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 2.73 Billion USD | -1.23% |
2022 | 2.76 Billion USD | 1.47% |
2021 | 2.72 Billion USD | 15.68% |
2020 | 2.35 Billion USD | -1.99% |
2019 | 2.4 Billion USD | 33.8% |
2018 | 1.79 Billion USD | -10.54% |
2017 | 2.01 Billion USD | 5.18% |
2016 | 1.91 Billion USD | 15.53% |
2015 | 1.65 Billion USD | -40.08% |
2014 | 2.76 Billion USD | 2.33% |
2013 | 2.69 Billion USD | 14.27% |
2012 | 2.36 Billion USD | 8.1% |
2011 | 2.18 Billion USD | -40.8% |
2010 | 3.69 Billion USD | 27.1% |
2009 | 2.9 Billion USD | 36.66% |
2008 | 2.12 Billion USD | 1.82% |
2007 | 2.08 Billion USD | 39.13% |
2006 | 1.5 Billion USD | 0.0% |
2005 | - USD | -100.0% |
2004 | 1.15 Billion USD | 0.0% |
2003 | 1.15 Billion USD | 0.0% |
2002 | 1.15 Billion USD | 19066.67% |
2001 | 6 Million USD | -94.55% |
2000 | 110 Million USD | 0.0% |
1999 | - USD | 0.0% |
1998 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 2.89 Billion USD | 6.51% |
2024 Q1 | 2.71 Billion USD | -0.59% |
2024 Q3 | 2.93 Billion USD | 7.6% |
2023 Q2 | 2.73 Billion USD | -8.01% |
2023 Q4 | 2.73 Billion USD | -1.94% |
2023 Q3 | 2.78 Billion USD | 2.05% |
2023 Q1 | 2.97 Billion USD | 7.3% |
2023 FY | 2.73 Billion USD | -1.23% |
2022 Q3 | 2.91 Billion USD | 0.24% |
2022 Q4 | 2.76 Billion USD | -4.91% |
2022 FY | 2.76 Billion USD | 1.47% |
2022 Q1 | 2.73 Billion USD | 0.04% |
2022 Q2 | 2.9 Billion USD | 6.41% |
2021 Q2 | 2.93 Billion USD | 17.33% |
2021 Q1 | 2.49 Billion USD | 5.93% |
2021 FY | 2.72 Billion USD | 15.68% |
2021 Q4 | 2.72 Billion USD | -4.51% |
2021 Q3 | 2.85 Billion USD | -2.52% |
2020 Q1 | 2.46 Billion USD | 2.29% |
2020 Q2 | 2.48 Billion USD | 1.06% |
2020 Q3 | 2.32 Billion USD | -6.63% |
2020 Q4 | 2.35 Billion USD | 1.55% |
2020 FY | 2.35 Billion USD | -1.99% |
2019 FY | 2.4 Billion USD | 33.8% |
2019 Q4 | 2.4 Billion USD | 33.87% |
2019 Q1 | 1.79 Billion USD | -0.06% |
2019 Q2 | 1.79 Billion USD | 0.0% |
2019 Q3 | 1.79 Billion USD | 0.0% |
2018 Q3 | 1.79 Billion USD | -14.94% |
2018 FY | 1.79 Billion USD | -10.54% |
2018 Q1 | 2.14 Billion USD | 6.66% |
2018 Q2 | 2.11 Billion USD | -1.4% |
2018 Q4 | 1.79 Billion USD | 0.0% |
2017 FY | 2.01 Billion USD | 5.18% |
2017 Q3 | 2.08 Billion USD | 1.86% |
2017 Q2 | 2.04 Billion USD | 2.56% |
2017 Q1 | 1.99 Billion USD | 4.18% |
2017 Q4 | 2.01 Billion USD | -3.36% |
2016 Q2 | 1.88 Billion USD | 9.0% |
2016 FY | 1.91 Billion USD | 15.53% |
2016 Q1 | 1.73 Billion USD | 4.71% |
2016 Q4 | 1.91 Billion USD | 1.32% |
2016 Q3 | 1.88 Billion USD | -0.11% |
2015 Q3 | 1.65 Billion USD | -0.06% |
2015 Q1 | 1.65 Billion USD | -39.97% |
2015 Q4 | 1.65 Billion USD | 0.0% |
2015 FY | 1.65 Billion USD | -40.08% |
2015 Q2 | 1.65 Billion USD | -0.12% |
2014 FY | 2.76 Billion USD | 2.33% |
2014 Q1 | 2.69 Billion USD | -0.15% |
2014 Q4 | 2.76 Billion USD | 24.64% |
2014 Q3 | 2.21 Billion USD | -17.71% |
2014 Q2 | 2.69 Billion USD | -0.07% |
2013 FY | 2.69 Billion USD | 14.27% |
2013 Q4 | 2.69 Billion USD | -0.07% |
2013 Q1 | 2.36 Billion USD | -0.04% |
2013 Q2 | 2.35 Billion USD | -0.21% |
2013 Q3 | 2.7 Billion USD | 14.64% |
2012 Q2 | 2.17 Billion USD | -0.18% |
2012 FY | 2.36 Billion USD | 8.1% |
2012 Q4 | 2.36 Billion USD | 6.68% |
2012 Q3 | 2.21 Billion USD | 1.7% |
2012 Q1 | 2.18 Billion USD | -0.18% |
2011 FY | 2.18 Billion USD | -40.8% |
2011 Q4 | 2.18 Billion USD | 0.78% |
2011 Q3 | 2.16 Billion USD | 1.12% |
2011 Q2 | 2.14 Billion USD | 0.23% |
2011 Q1 | 2.13 Billion USD | -42.05% |
2010 FY | 3.69 Billion USD | 27.1% |
2010 Q3 | 3.67 Billion USD | 27.09% |
2010 Q2 | 2.89 Billion USD | -0.58% |
2010 Q1 | 2.91 Billion USD | 0.24% |
2010 Q4 | 3.69 Billion USD | 0.35% |
2009 Q2 | 2.15 Billion USD | -2.27% |
2009 Q1 | 2.2 Billion USD | 3.72% |
2009 FY | 2.9 Billion USD | 36.66% |
2009 Q3 | 2.15 Billion USD | -0.05% |
2009 Q4 | 2.9 Billion USD | 34.88% |
2008 Q3 | 2.31 Billion USD | -2.49% |
2008 Q2 | 2.37 Billion USD | 11.67% |
2008 FY | 2.12 Billion USD | 1.82% |
2008 Q4 | 2.12 Billion USD | -8.21% |
2008 Q1 | 2.12 Billion USD | 1.87% |
2007 Q2 | 1.5 Billion USD | 0.0% |
2007 Q4 | 2.08 Billion USD | 39.13% |
2007 FY | 2.08 Billion USD | 39.13% |
2007 Q1 | 1.5 Billion USD | 0.0% |
2007 Q3 | 1.5 Billion USD | 0.0% |
2006 Q1 | 1.5 Billion USD | 0.0% |
2006 FY | 1.5 Billion USD | 0.0% |
2006 Q4 | 1.5 Billion USD | 0.0% |
2006 Q3 | 1.5 Billion USD | 0.0% |
2006 Q2 | 1.5 Billion USD | 0.0% |
2005 Q3 | 1.15 Billion USD | 0.0% |
2005 Q4 | - USD | -100.0% |
2005 Q1 | 1.15 Billion USD | 0.0% |
2005 Q2 | 1.15 Billion USD | 0.0% |
2005 FY | - USD | -100.0% |
2004 Q2 | 1.15 Billion USD | 0.0% |
2004 Q1 | 1.15 Billion USD | 0.0% |
2004 FY | 1.15 Billion USD | 0.0% |
2004 Q3 | 1.15 Billion USD | 0.0% |
2004 Q4 | 1.15 Billion USD | 0.0% |
2003 FY | 1.15 Billion USD | 0.0% |
2003 Q4 | 1.15 Billion USD | 0.0% |
2003 Q3 | 1.15 Billion USD | 0.0% |
2003 Q1 | 1.15 Billion USD | 0.0% |
2003 Q2 | 1.15 Billion USD | 0.0% |
2002 Q2 | 1.15 Billion USD | 0.0% |
2002 Q3 | 1.15 Billion USD | 0.0% |
2002 Q4 | 1.15 Billion USD | 0.0% |
2002 FY | 1.15 Billion USD | 19066.67% |
2002 Q1 | 1.15 Billion USD | 19066.67% |
2001 Q4 | 6 Million USD | -99.24% |
2001 Q3 | 794 Million USD | 2.72% |
2001 Q2 | 773 Million USD | 39.03% |
2001 FY | 6 Million USD | -94.55% |
2001 Q1 | 556 Million USD | 405.45% |
2000 Q1 | 997 Million USD | 0.0% |
2000 Q2 | 98 Million USD | -90.17% |
2000 Q3 | 129 Million USD | 31.63% |
2000 FY | 110 Million USD | 0.0% |
2000 Q4 | 110 Million USD | -14.73% |
1999 Q4 | - USD | 0.0% |
1999 FY | - USD | 0.0% |
1998 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -7385.767% |
Dynavax Technologies Corporation | 256.91 Million USD | -964.559% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -6486.077% |
Perrigo Company plc | 4.07 Billion USD | 32.857% |
Illumina, Inc. | 2.26 Billion USD | -20.911% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 92.167% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -273400.0% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 71.373% |
IQVIA Holdings Inc. | 14.23 Billion USD | 80.781% |
Heron Therapeutics, Inc. | 173.75 Million USD | -1474.074% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -1.188% |
Unity Biotechnology, Inc. | 26.99 Million USD | -10033.383% |
Waters Corporation | 2.35 Billion USD | -16.111% |
Biogen Inc. | 7.33 Billion USD | 62.729% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -7077.724% |
Evolus, Inc. | 126.54 Million USD | -2061.269% |
Adicet Bio, Inc. | 17.7 Million USD | -15349.359% |
Cara Therapeutics, Inc. | 43.16 Million USD | -6235.858% |
bluebird bio, Inc. | 330.32 Million USD | -727.97% |
Esperion Therapeutics, Inc. | 540.94 Million USD | -405.595% |
FibroGen, Inc. | 170.45 Million USD | -1504.529% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -12996.005% |
Homology Medicines, Inc. | 44.05 Million USD | -6108.29% |
Geron Corporation | 85.89 Million USD | -3083.972% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | -14.053% |
Amicus Therapeutics, Inc. | 445.05 Million USD | -514.525% |
Myriad Genetics, Inc. | 145 Million USD | -1786.207% |
Viking Therapeutics, Inc. | 1.26 Million USD | -216963.492% |
Intellia Therapeutics, Inc. | 115.34 Million USD | -2271.127% |
Zoetis Inc. | 6.8 Billion USD | 59.797% |
Abeona Therapeutics Inc. | 4.4 Million USD | -62030.85% |
Mettler-Toledo International Inc. | 2.16 Billion USD | -26.167% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -141.208% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -238.323% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -7429.664% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -88.161% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -4625.947% |
Verastem, Inc. | 41.55 Million USD | -6481.322% |
Nektar Therapeutics | 230.4 Million USD | -1087.061% |
Axsome Therapeutics, Inc. | 186.37 Million USD | -1367.495% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -88872.023% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | -95.804% |
OPKO Health, Inc. | 326.56 Million USD | -737.508% |
Exelixis, Inc. | 189.94 Million USD | -1339.898% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | -538.422% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -1811158.278% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | -1876.028% |
Imunon, Inc. | 1.13 Million USD | -239961.161% |
Blueprint Medicines Corporation | 774.12 Million USD | -253.303% |
Insmed Incorporated | 1.2 Billion USD | -127.161% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | -82.425% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -4699.256% |
TG Therapeutics, Inc. | 110.79 Million USD | -2368.523% |
Incyte Corporation | 38.28 Million USD | -7043.417% |
Emergent BioSolutions Inc. | 877.5 Million USD | -211.681% |